CORD-19:775b90287b44353bee979abb0970a4666022f86d / 775236-775502 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T74232","span":{"begin":0,"end":266},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The objective of this clinical trial was to evaluate the safety and efficacy of the 0.10% and 0.15% azelastine formulations compared to placebo at a dosage of 1 spray per nostril twice daily in pediatric patients ≥6 to \u003c12 yrs with perennial allergic rhinitis (PAR)."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T392","span":{"begin":0,"end":266},"obj":"Sentence"}],"text":"The objective of this clinical trial was to evaluate the safety and efficacy of the 0.10% and 0.15% azelastine formulations compared to placebo at a dosage of 1 spray per nostril twice daily in pediatric patients ≥6 to \u003c12 yrs with perennial allergic rhinitis (PAR)."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5808","span":{"begin":232,"end":259},"obj":"Disease"},{"id":"T5810","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"T5811","span":{"begin":251,"end":259},"obj":"Disease"},{"id":"T8802","span":{"begin":232,"end":259},"obj":"Disease"},{"id":"T63147","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"T79781","span":{"begin":251,"end":259},"obj":"Disease"}],"attributes":[{"id":"A5808","pred":"mondo_id","subj":"T5808","obj":"http://purl.obolibrary.org/obo/MONDO_0011786"},{"id":"A5809","pred":"mondo_id","subj":"T5808","obj":"http://purl.obolibrary.org/obo/MONDO_0024332"},{"id":"A5810","pred":"mondo_id","subj":"T5810","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A5811","pred":"mondo_id","subj":"T5811","obj":"http://purl.obolibrary.org/obo/MONDO_0003014"},{"id":"A12590","pred":"mondo_id","subj":"T8802","obj":"http://purl.obolibrary.org/obo/MONDO_0011786"},{"id":"A73666","pred":"mondo_id","subj":"T8802","obj":"http://purl.obolibrary.org/obo/MONDO_0024332"},{"id":"A79362","pred":"mondo_id","subj":"T63147","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A44112","pred":"mondo_id","subj":"T79781","obj":"http://purl.obolibrary.org/obo/MONDO_0003014"}],"text":"The objective of this clinical trial was to evaluate the safety and efficacy of the 0.10% and 0.15% azelastine formulations compared to placebo at a dosage of 1 spray per nostril twice daily in pediatric patients ≥6 to \u003c12 yrs with perennial allergic rhinitis (PAR)."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T4057","span":{"begin":242,"end":259},"obj":"Phenotype"}],"attributes":[{"id":"A4057","pred":"hp_id","subj":"T4057","obj":"http://purl.obolibrary.org/obo/HP_0003193"}],"text":"The objective of this clinical trial was to evaluate the safety and efficacy of the 0.10% and 0.15% azelastine formulations compared to placebo at a dosage of 1 spray per nostril twice daily in pediatric patients ≥6 to \u003c12 yrs with perennial allergic rhinitis (PAR)."}